Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for
activation. Mutations that constitutively activate ERα without the need for hormone binding …

A significant number of estrogen receptor α (ERα)-positive breast tumors develop resistance
to endocrine therapy and recur with metastatic disease. Several mechanisms of endocrine …

Seventy percent of breast cancers express estrogen receptor (ER), and most of these are
sensitive to ER inhibition. However, many such tumors for unknown reasons become …

Breast cancer (BC) is the most common cancer among women worldwide. More than 70% of
BC cases express estrogen receptor alpha (ERα), a central transcription factor that …

Estrogens play a crucial role in regulating the growth and differentiation of breast cancers,
with approximately two thirds of all breast tumors expressing the estrogen receptor alpha …

Approximately 70% of breast cancers are oestrogen receptor α (ER) positive, and are,
therefore, treated with endocrine therapies. However, about 25% of patients with primary …

Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast
tumors. Although endocrine therapy targeting ER is highly effective, intrinsic or acquired …

Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and
D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies …

Resistance to endocrine therapy occurs in virtually all patients with estrogen receptor α
(ERα)-positive metastatic breast cancer, and is attributed to various mechanisms including …

Estrogen receptor α (ER) ligand-binding domain (LBD) mutations are found in a substantial
number of endocrine treatment-resistant metastatic ER-positive (ER+) breast cancers. We …